{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:57:14Z","timestamp":1787313434748,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["22-15-00098-P"],"award-info":[{"award-number":["22-15-00098-P"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["22-15-00098-P"],"award-info":[{"award-number":["22-15-00098-P"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate-specific membrane antigen (PSMA) is an essential zinc-dependent metalloprotease classified within the type II transmembrane protein family, often referred to as glutamate carboxypeptidase II (GCPII). PSMA is recognized as a particularly promising target for both the diagnosis and therapeutic intervention of prostate cancer. In this study, we designed and synthesized PSMA-targeted DOTA-loaded bimodal conjugate 11 with SulfoCy5 fluorescent dye, performed in vitro characterization, and analyzed biodistribution in vivo. At 40\u2013100 nM concentrations, the resulting conjugate demonstrated reliable visualization of tumor cells, on par with the reference PSMA-SylfoCy5 compound. In vivo biodistribution analysis of [68Ga]Ga-11 in mice demonstrated a reduction in renal accumulation in comparison with dye-free conjugate [68Ga]Ga-10. The specificity of [68Ga]Ga-11 for PSMA was confirmed in a murine LNCaP xenograft model: its effective accumulation in tumors and kidneys, as well as relatively rapid elimination from non-target tissues, make it a promising agent for PET imaging but not radionuclide therapy.<\/jats:p>","DOI":"10.3390\/ijms27083502","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:24:58Z","timestamp":1776176698000},"page":"3502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bimodal Fluorescent Conjugate Based on Prostate-Specific Membrane Antigen Ligands with the Chelating Agent DOTA and SulfoCy5 Dye: Synthesis, Radiolabeling, and Biological Activity"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-0346","authenticated-orcid":false,"given":"Aleksei E.","family":"Machulkin","sequence":"first","affiliation":[{"name":"Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1\/3, GSP-1, 119991 Moscow, Russia"},{"name":"Department of Biochemistry, People\u2019s Friendship University of Russia Named After Patrice Lumumba (RUDN University), 117198 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6000-6100","authenticated-orcid":false,"given":"Stanislav A.","family":"Petrov","sequence":"additional","affiliation":[{"name":"Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1\/3, GSP-1, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina S.","family":"Butakova","sequence":"additional","affiliation":[{"name":"Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1\/3, GSP-1, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr S.","family":"Lunev","sequence":"additional","affiliation":[{"name":"FSBI State Research Center\u2014Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123098 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-9873","authenticated-orcid":false,"given":"Kristina A.","family":"Petrosova","sequence":"additional","affiliation":[{"name":"FSBI State Research Center\u2014Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123098 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9349-5211","authenticated-orcid":false,"given":"Radik R.","family":"Shafikov","sequence":"additional","affiliation":[{"name":"Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1\/3, GSP-1, 119991 Moscow, Russia"},{"name":"Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Skvortsov","sequence":"additional","affiliation":[{"name":"Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1\/3, GSP-1, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-8507","authenticated-orcid":false,"given":"Iurii A.","family":"Mitrofanov","sequence":"additional","affiliation":[{"name":"FSBI State Research Center\u2014Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123098 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6026-0329","authenticated-orcid":false,"given":"Mariia N.","family":"Ivashkovaskaia","sequence":"additional","affiliation":[{"name":"FSBI State Research Center\u2014Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123098 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6796-8241","authenticated-orcid":false,"given":"Elena K.","family":"Beloglazkina","sequence":"additional","affiliation":[{"name":"Chemistry Department, Lomonosov Moscow State University, Leninskie Gory, Building 1\/3, GSP-1, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4810-4346","authenticated-orcid":false,"given":"Anton A.","family":"Larenkov","sequence":"additional","affiliation":[{"name":"FSBI State Research Center\u2014Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, 123098 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1536012118776068","DOI":"10.1177\/1536012118776068","article-title":"PSMA Theranostics: Current Status and Future Directions","volume":"17","author":"Rahbar","year":"2018","journal-title":"Mol. Imaging"},{"key":"ref_2","first-page":"229","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132010, Featuring Prevalence of Comorbidity and Impact on Survival among Persons with Lung, Colorectal, Breast, or Prostate Cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_6","first-page":"10","article-title":"Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"12","author":"Sun","year":"2020","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/med.21508","article-title":"Targeting Prostate Cancer: Prostate-Specific Membrane Antigen Based Diagnosis and Therapy","volume":"39","author":"Haberkorn","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.bmcl.2009.10.061","article-title":"Bioisosterism of Urea-Based GCPII Inhibitors: Synthesis and Structure-Activity Relationship Studies","volume":"20","author":"Wang","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_9","first-page":"927","article-title":"Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients","volume":"7","author":"Horoszewicz","year":"1987","journal-title":"Anticancer. Res."},{"key":"ref_10","first-page":"2321","article-title":"Enhanced Expression of Prostate-Specific Membrane Antigen Gene in Prostate Cancer as Revealed by in Situ Hybridization","volume":"57","author":"Kawakami","year":"1997","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate Specific Membrane Antigen Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Study of 184 Cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"ref_12","first-page":"3192","article-title":"Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res."},{"key":"ref_13","first-page":"3629","article-title":"Monoclonal Antibodies to the Extracellular Domain of Prostate-Specific Membrane Antigen Also React with Tumor Vascular Endothelium","volume":"57","author":"Liu","year":"1997","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","article-title":"Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Neovasculature of Renal Neoplasms","volume":"70","author":"Baccala","year":"2007","journal-title":"Urology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.humpath.2009.06.003","article-title":"Prostate-Specific Membrane Antigen Expression in the Neovasculature of Gastric and Colorectal Cancers","volume":"40","author":"Haffner","year":"2009","journal-title":"Hum. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme","volume":"135","author":"Wernicke","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate Specific Membrane Antigen (PSMA) Expression in Primary Gliomas and Breast Cancer Brain Metastases","volume":"14","author":"Lambert","year":"2014","journal-title":"Cancer Cell Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.2011.112","article-title":"Folate Hydrolase (Prostate-Specific Antigen) 1 Expression in Bladder Cancer Subtypes and Associated Tumor Neovasculature","volume":"24","author":"Samplaski","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-Labeled J591 Anti-PSMA Antibody for Vascular Targeted Imaging in Progressive Solid Tumors","volume":"5","author":"Divgi","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by Radioligands in Non-Prostate Disease\u2014Current Status and Future Perspectives","volume":"45","author":"Backhaus","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s10517-016-3490-3","article-title":"Nanohybride Materials Based on Magnetite-Gold Nanoparticles for Diagnostics of Prostate Cancer: Synthesis and in Vitro Testing","volume":"161","author":"Machulkin","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Garanina, A.S., Efremova, M.V., Machulkin, A.E., Lyubin, E.V., Vorobyeva, N.S., Zhironkina, O.A., Strelkova, O.S., Kireev, I.I., Alieva, I.B., and Uzbekov, R.E. (2022). Bifunctional Magnetite\u2013Gold Nanoparticles for Magneto-Mechanical Actuation and Cancer Cell Destruction. Magnetochemistry, 8.","DOI":"10.3390\/magnetochemistry8120185"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129712","DOI":"10.1016\/j.bmcl.2024.129712","article-title":"A PSMA-Targeted Doxorubicin Small-Molecule Drug Conjugate","volume":"104","author":"Yoon","year":"2024","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1134\/S1070363225605721","article-title":"Organic Chemistry in the Creation of Molecules with Practically Useful Properties","volume":"96","author":"Belyakova","year":"2026","journal-title":"Russ. J. Gen. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1535-7163.MCT-24-0750","article-title":"PSMA-Targeted Small Molecule\u2013Drug Conjugates Based on a Postprolyl Peptidase\u2013Cleavable Linker for the Treatment of Prostate Cancer","volume":"24","author":"Georgiev","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1021\/acs.bioconjchem.5c00099","article-title":"Evaluation of PSMA-Targeted TREN-CAM Conjugates for Targeted Imaging of Cancer with 68Ga(III) and 45Ti(IV)","volume":"36","author":"Marlin","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"118433","DOI":"10.1016\/j.ejmech.2025.118433","article-title":"A Series of Conjugates Based on Prostate-Specific Membrane Antigen Ligands with the Chelating Agent DOTA: Synthesis, Radiolabeling, and Biological Activity","volume":"303","author":"Butakova","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00259-023-06474-z","article-title":"Mono- and Multimeric PSMA-Targeting Small Molecule-Thorium-227 Conjugates for Optimized Efficacy and Biodistribution in Preclinical Models","volume":"51","author":"Indrevoll","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acs.bioconjchem.5c00033","article-title":"Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr","volume":"36","author":"Petrov","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/acsptsci.4c00070","article-title":"Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu","volume":"7","author":"Machulkin","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer","volume":"56","author":"Kopka","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","article-title":"Synthesis and Evaluation of a Novel Urea-Based 68Ga-Complex for Imaging PSMA Binding in Tumor","volume":"59","author":"Zha","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/bc2002715","article-title":"Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched Humanized J591 Antibody\u2013Indocyanine Green (ICG) Conjugate","volume":"22","author":"Nakajima","year":"2011","journal-title":"Bioconjugate Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1078-0432.CCR-15-0503","article-title":"Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time","volume":"22","author":"Sonn","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3762\/bjoc.14.244","article-title":"Novel Solid-Phase Strategy for the Synthesis of Ligand-Targeted Fluorescent-Labelled Chelating Peptide Conjugates as a Theranostic Tool for Cancer","volume":"14","author":"Sengupta","year":"2018","journal-title":"Beilstein J. Org. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2967\/jnumed.117.201293","article-title":"PSMA-11\u2013Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer","volume":"59","author":"Baranski","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1002\/anie.201102872","article-title":"Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen","volume":"50","author":"Banerjee","year":"2011","journal-title":"Angew. Chem.-Int. Ed."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2967\/jnumed.119.233064","article-title":"Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction","volume":"61","author":"Hensbergen","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1021\/acs.jmedchem.8b00240","article-title":"18F-Positron Emitting\/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management","volume":"61","author":"Kommidi","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.118.212720","article-title":"Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer","volume":"60","author":"Schottelius","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.7150\/thno.52166","article-title":"Theranostics Photosensitizer-Based Multimodal PSMA-Targeting Ligands for Intraoperative Detection of Prostate Cancer","volume":"11","author":"Derks","year":"2021","journal-title":"Theranostics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"113752","DOI":"10.1016\/j.ejmech.2021.113752","article-title":"PSMA-Targeted Low-Molecular Double Conjugates for Diagnostics and Therapy","volume":"225","author":"Petrov","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.mencom.2020.11.022","article-title":"Influence of the Dipeptide Linker Configuration on the Activity of PSMA Ligands","volume":"30","author":"Uspenskaya","year":"2020","journal-title":"Mendeleev Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1021\/acs.bioconjchem.5c00139","article-title":"Fluorescent PSMA-Targeted Radiotheranostic Compounds for Multiscale Imaging","volume":"36","author":"Simpson","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Eder, A.-C., Matthias, J., Sch\u00e4fer, M., Schmidt, J., Steinacker, N., Bauder-W\u00fcst, U., Domogalla, L.-C., Roscher, M., Haberkorn, U., and Eder, M. (2022). A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030267"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"16645","DOI":"10.1021\/acs.jmedchem.5c01480","article-title":"Synthesis and Preclinical Evaluation of Dual-Mode Fluorescent 18F-PET Tracers Targeting PSMA","volume":"68","author":"Lozada","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"108938","DOI":"10.1016\/j.nucmedbio.2024.108938","article-title":"Evaluation of a Bimodal, Matched Pair Theranostic Agent Targeting Prostate-Specific Membrane Antigen","volume":"136\u2013137","author":"Lewis","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1021\/acs.jmedchem.0c01935","article-title":"Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them","volume":"64","author":"Machulkin","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s11307-014-0747-y","article-title":"Targeted Radionuclide and Fluorescence Dual-Modality Imaging of Cancer: Preclinical Advances and Clinical Translation","volume":"16","author":"Rijpkema","year":"2014","journal-title":"Mol. Imaging Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s44303-026-00150-1","article-title":"Advanced Imaging Techniques for Tumor Intraoperative Navigation Imaging","volume":"4","author":"Li","year":"2026","journal-title":"npj Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jphotobiol.2016.12.018","article-title":"A PSMA-Targeted Theranostic Agent for Photodynamic Therapy","volume":"167","author":"Chen","year":"2017","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1021\/acs.bioconjchem.9b00758","article-title":"Image-Guided Surgery: Are We Getting the Most out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?","volume":"31","author":"Hensbergen","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177Lu-Labeled Albumin-Binder\u2013Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hirata, S., Echigo, H., Munekane, M., Mishiro, K., Washiyama, K., Fuchigami, T., Wakabayashi, H., Takahashi, K., Kinuya, S., and Ogawa, K. (2025). Engineering a Radiohybrid PSMA Ligand with an Albumin-Binding Moiety and Pharmacokinetic Modulation via an Albumin-Binding Competitor for Radiotheranostics. Molecules, 30.","DOI":"10.3390\/molecules30132804"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1021\/acs.molpharmaceut.7b00877","article-title":"Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1021\/acs.molpharmaceut.5c00693","article-title":"Albumin Binding as a Strategy for Improving Tumor Targeting of Radiolabeled Compounds","volume":"22","author":"Rahmati","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_59","unstructured":"Tietze, L., Eicher, T., Diederichsen, U., Speicher, A., and Sch\u00fctzenmeister, N. (2015). Reactions and Synthesis in the Organic Chemistry Laboratory, John Wiley & Sons."},{"key":"ref_60","first-page":"1120","article-title":"Radiochemical Purity of 68Ga-BCA-Peptides: Separation of All 68Ga Species with a Single ITLC Strip","volume":"10","author":"Larenkov","year":"2016","journal-title":"World Acad. Sci. Eng. Technol. Int. J. Chem. Mol. Nucl. Mater. Metall. Eng."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10967-019-06964-1","article-title":"Determination of Ionic 68Ga Impurity in Radiopharmaceuticals: Major Revision of Radio-HPLC Methods","volume":"323","author":"Maruk","year":"2020","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Staniszewska, M., Fragoso Costa, P., Eiber, M., Klose, J.M., Wosniack, J., Reis, H., Szarvas, T., Hadaschik, B., L\u00fcckerath, K., and Herrmann, K. (2021). Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147431"},{"key":"ref_63","unstructured":"Parliament, European, and Council, European (2010). Directive 2010\/63\/EU of the European Parliament and of the Council on the Protection of Animals Used for Scientific Purposes. EU Off. J., 276, 33\u201379."},{"key":"ref_64","unstructured":"(2026, April 10). Decision of Council of the Eurasian Economic Commission of November 3, 2016 No. 87 \u201cAmendments to the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union\u201d. Available online: https:\/\/eec.eaeunion.org\/upload\/medialibrary\/eb1\/EECC-Decision-_-87-Rules-of-Good-Pharmacovigilance-Practice-of-the-Eurasian-Economic-Union.pdf."},{"key":"ref_65","first-page":"148","article-title":"The Experience of Colorectal Cancer Xenograft Heterotopic Modeling of Various Cell Types on Athymic BALB\/c Nude Mice","volume":"64","author":"Lunyova","year":"2020","journal-title":"Pat. Phys. Exp. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/026119290203002S36","article-title":"Directive 86\/609\/EEC on the Protection of Animals Used for Experimental and Other Scientific Purposes","volume":"30","author":"Louhimies","year":"2003","journal-title":"Altern. Lab. Anim."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:52:09Z","timestamp":1777006329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":66,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27083502"],"URL":"https:\/\/doi.org\/10.3390\/ijms27083502","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}